Abrysvo and Arexvy: be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults

Obviously, the advice from the MHRA is concerning. We would always be worried about any increased risk of Guillain-Barré Syndrome for anyone. GBS is a potentially life altering condition that has a significant impact on people and families, and we want to see the risk of GBS reduced wherever possible. Thankfully, GBS is a very rare condition with between 1-2 people impacted by it per 100,000, so that is about 1000 people per year in the UK. Any increase in that number is heartbreaking, but the chances of developing GBS following the RSV vaccine is very small (the reported issue is 21 cases from 1.9M doses, which is around 1 in 90,000 or 0.001%). 

However, any risk needs to be considered, and we would always advise anyone worried about having the vaccine to discuss it with their GP or a healthcare professional. The risk of the jab needs to be weighed up against the risk of catching what the vaccine is trying to prevent.

We welcome the clarity from MHRA on this, and the advice for healthcare professionals to warn about GBS and to watch for symptoms, which can be varied. If people are worried then they should contact their GP or 111 immediately. More information about GBS can be found on our website at GBS Info Hub | Inflammatory Neuropathies UK

If anyone is concerned and wants to talk to us then they can call on 01529 469910, or email hello@inflammatoryneuropathies.uk.